Dr. Prabhakar reports no financial relationships relevant to this field of study.SYNOPSIS:
In this Phase 2 trial, 105 older patients with acute myeloid leukemia who were either treatment-naïve or at first relapse were treated with one of three schedules of oral sapacitabine: 200 mg twice daily for 7 days (group A), 300 mg twice daily for 7 days (group B), or 400 mg twice daily for 3 days each week for 2 weeks (group C). The treatment was well tolerated with I -year overall survival of 35%, 10%, and 30% in groups A, B, and C, respectively. The 400 mg dose schedule had the best efficacy profile. A platelet count of ≤ 50 × 109/L and an unfavorable cytogentic risk profile were adverse prognostic factors for I -year overall survival.SOURCE:
Kantarjian H, et al. Oral sapacitabine for the treatment of acute myeloid leukemia in elderly patients: A randomized phase 2 study. Lancet Oncol 2012; 13:1096-1104.